{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:13:19Z","timestamp":1776795199255,"version":"3.51.2"},"reference-count":106,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Genese","award":["PGG\/006\/2016."],"award-info":[{"award-number":["PGG\/006\/2016."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>When the first cases of HIV infection appeared in the 1980s, AIDS was a deadly disease without any therapeutic alternatives. Currently, there is still no cure for most cases mainly due to the multiple tissues that act as a reservoir for this virus besides the high viral mutagenesis that leads to an antiretroviral drug resistance. Throughout the years, multiple drugs with specific mechanisms of action on distinct targets have been approved. In this review, the most recent phase III clinical studies and other research therapies as advanced antiretroviral nanodelivery systems will be here discussed. Although the combined antiretroviral therapy is effective in reducing viral loading to undetectable levels, it also presents some disadvantages, such as usual side effects, high frequency of administration, and the possibility of drug resistance. Therefore, several new drugs, delivery systems, and vaccines have been tested in pre-clinical and clinical trials. Regarding drug delivery, an attempt to change the route of administration of some conventional antiretrovirals has proven to be successful and surpassed some issues related to patient compliance. Nanotechnology has brought a new approach to overcoming certain obstacles of formulation design including drug solubility and biodistribution. Overall, the encapsulation of antiretroviral drugs into nanosystems has shown improved drug release and pharmacokinetic profile.<\/jats:p>","DOI":"10.3390\/molecules26175305","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:59:45Z","timestamp":1630447185000},"page":"5305","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Novel Antiretroviral Therapeutic Strategies for HIV"],"prefix":"10.3390","volume":"26","author":[{"given":"Rita F.","family":"Cunha","sequence":"first","affiliation":[{"name":"Drug Delivery Research Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5685-1790","authenticated-orcid":false,"given":"Sandra","family":"Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Drug Delivery Research Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6028-4717","authenticated-orcid":false,"given":"Manuela","family":"Carvalheiro","sequence":"additional","affiliation":[{"name":"Drug Delivery Research Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"given":"Jos\u00e9 M. Azevedo","family":"Pereira","sequence":"additional","affiliation":[{"name":"Host-Pathogen Interactions Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"given":"Quirina","family":"Costa","sequence":"additional","affiliation":[{"name":"Host-Pathogen Interactions Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8727-0614","authenticated-orcid":false,"given":"Andreia","family":"Ascenso","sequence":"additional","affiliation":[{"name":"Drug Delivery Research Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: Epidemiology, pathogenesis, treatment, and prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"ref_2","unstructured":"UNAIDS (2019, November 10). Global HIV & AIDS Statistics\u20142019 Fact Sheet. Available online: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"(2016). German Advisory Committee Blood (Arbeitskreis Blut), Subgroup \u2018Assessment of Pathogens Transmissible by Blood\u2019 GACB (Arbeitskreis, Blood\u2019 S \u2018Assessment of PT by. Human immunodeficiency virus (HIV). Transfus. Med. Hemother., 43, 203\u2013222.","DOI":"10.1159\/000445852"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"a006866","DOI":"10.1101\/cshperspect.a006866","article-title":"HIV: Cell binding and entry","volume":"2","author":"Wilen","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Schaller, T., Ocwieja, K., Rasaiyaah, J., Price, A.J., Brady, T.L., Roth, S.L., Hu\u00e9, S., Fletcher, A.J., Lee, K., and KewalRamani, V.N. (2011). HIV-1 Capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002439"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2019467118","DOI":"10.1073\/pnas.2019467118","article-title":"HIV-1 cores retain their integrity until minutes before uncoating in the nucleus","volume":"118","author":"Li","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3389\/fmicb.2021.652486","article-title":"HIV-1 capsid core: A bullet to the heart of the target cell","volume":"12","author":"Toccafondi","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jcv.2005.09.004","article-title":"Basics of the virology of HIV-1 and its replication","volume":"34","author":"Sierra","year":"2005","journal-title":"J. Clin. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.spid.2003.09.007","article-title":"Molecular biology of the human immunodeficiency virus: Current and future targets for intervention","volume":"14","author":"Krogstad","year":"2003","journal-title":"Semin. Pediatr. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrmicro2747","article-title":"The structural biology of HIV-1: Mechanistic and therapeutic insights","volume":"10","author":"Engelman","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1742-4690-10-5","article-title":"Wrapping up the bad news\u2014HIV assembly and release","volume":"10","author":"Meng","year":"2013","journal-title":"Retrovirology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"a006965","DOI":"10.1101\/cshperspect.a006965","article-title":"HIV transmission","volume":"2","author":"Shaw","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMra1011874","article-title":"Acute HIV-1 infection","volume":"364","author":"Cohen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_14","first-page":"5","article-title":"HIV virology and pathogenetic mechanisms of infection: A brief overview","volume":"46","author":"Raimundo","year":"2010","journal-title":"Ann. Ist. Super Sanita."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fpubh.2017.00032","article-title":"HIV diagnosis and treatment through advanced technologies","volume":"5","author":"Zulfiqar","year":"2017","journal-title":"Front. Public Health"},{"key":"ref_16","unstructured":"Kemnic, T.R., and Gulick, P.G. (2019). HIV Antiretroviral Therapy, StatPearls Publishing."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/0253-7613.96296","article-title":"Antiretroviral drugs: Critical issues and recent advances","volume":"44","author":"Desai","year":"2012","journal-title":"Indian J. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"a007161","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 Antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3851\/IMP2896","article-title":"The discovery and development of antiretroviral agents","volume":"19","author":"Lange","year":"2014","journal-title":"Antivir. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/bmj.322.7299.1410","article-title":"ABC of AIDS. Antiretroviral drugs","volume":"322","author":"Weller","year":"2001","journal-title":"BMJ"},{"key":"ref_21","first-page":"277","article-title":"Maraviroc\u2014A CCR5 antagonist for the treatment of HIV-1 infection","volume":"6","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_22","unstructured":"CHMP (2019, September 17). Celsentri\u2014EPAR Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/celsentri."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/jac\/dkq261","article-title":"Ibalizumab: An anti-CD4 monoclonal antibody for the treatment of HIV-1 infection","volume":"65","author":"Bruno","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1060028017717018","article-title":"Cobicistat versus ritonavir: Similar pharmacokinetic enhancers but some important differences","volume":"51","author":"Tseng","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"ref_25","first-page":"1","article-title":"Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy","volume":"8","year":"2016","journal-title":"HIV AIDS (Auckl.)"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.bbamem.2011.06.020","article-title":"Multifaceted action of Fuzeon as virus\u2013cell membrane fusion inhibitor","volume":"1808","author":"Ashkenazi","year":"2011","journal-title":"Biochim. et Biophys. Acta (BBA)-Biomembr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00831-17","DOI":"10.1128\/JVI.00831-17","article-title":"Enfuvirtide (T20)-based lipopeptide is a potent HIV-1 cell fusion inhibitor: Implications for viral entry and inhibition","volume":"91","author":"Ding","year":"2017","journal-title":"J. Virol."},{"key":"ref_28","first-page":"139","article-title":"Enfuvirtide, the first fusion inhibitor to treat HIV infection","volume":"7","author":"Poveda","year":"2005","journal-title":"Aids Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/TCRM.S1962","article-title":"Enfuvirtide antiretroviral therapy in HIV-1 infection","volume":"4","author":"Kitchen","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_30","unstructured":"AIDSinfo (2019, September 17). FDA Approval of HIV Medicines, Available online: https:\/\/aidsinfo.nih.gov\/understanding-hiv-aids\/infographics\/25\/fda-approval-of-hiv-medicines."},{"key":"ref_31","unstructured":"CHMP (2019, September 17). Prezista. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/prezista."},{"key":"ref_32","unstructured":"Agency, E.M. (2019, September 17). Vitekta: Withdrawal of the Marketing Authorisation in the European Union. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-vitekta-withdrawal-marketing-authorisation-european-union_en.pdf."},{"key":"ref_33","unstructured":"(2019, September 17). HIV\/AIDS Historical Time Line 1995-1999, Available online: https:\/\/www.fda.gov\/patients\/hiv-timeline-and-history-approvals\/hivaids-historical-time-line-1995-1999."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1074\/jbc.RA118.001729","article-title":"Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus","volume":"293","author":"Zhu","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Pu, J., Wang, Q., Xu, W., Lu, L., and Jiang, S. (2019). Development of protein- and peptide-based HIV entry inhibitors targeting gp120 or gp41. Viruses, 11.","DOI":"10.3390\/v11080705"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chong, H., Xue, J., Zhu, Y., Cong, Z., Chen, T., Wei, Q., Qin, C., and He, Y. (2019). Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007552"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.2147\/DDDT.S90580","article-title":"Maraviroc: A review of its use in HIV infection and beyond","volume":"ume 9","author":"Kanmogne","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_38","unstructured":"CHMP (2019, September 17). Genvoya, INN-Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide (as Fumarate). Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2018\/20180726141477\/anx_141477_pt.pdf."},{"key":"ref_39","unstructured":"CHMP (2019, September 17). Atripla, INN-Efavirenz\/Emtricitabine\/Tenofovir Disoproxil (as Fumarate)\u2014Annex I Summary of Product Characteristics. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2010\/2010031574930\/anx_74930_en.pdf."},{"key":"ref_40","unstructured":"CHMP (2019, September 17). Rezolsta, INN-Darunavir, Cobicistat\u2014Annex I Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rezolsta."},{"key":"ref_41","unstructured":"CHMP (2019, September 17). Triumeq, INN-Dolutegravir, Abacavir\u2014Annex I Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/triumeq-epar-product-information_en.pdf."},{"key":"ref_42","unstructured":"CHMP (2019, September 17). Evotaz, Atazanavir\/Cobicistat- Annex I Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evotaz."},{"key":"ref_43","unstructured":"CHMP (2019, September 17). Descovy, INN-Emtricitabine\/Tenofovir Alafenamide\u2014Annex I Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/descovy."},{"key":"ref_44","first-page":"1","article-title":"Advancements in developing strategies for sterilizing and functional HIV cures","volume":"2017","author":"Xu","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2515135518800689","article-title":"Broadly neutralizing antibodies in HIV-1 treatment and prevention","volume":"6","author":"Kumar","year":"2018","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Awi, N.J., and Teow, S.-Y. (2018). Antibody-mediated therapy against HIV\/AIDS: Where are we standing now?. J. Pathog., 1\u20139.","DOI":"10.1155\/2018\/8724549"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40265-018-0907-5","article-title":"Ibalizumab: First global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref_48","unstructured":"CHMP (2021, May 28). Trogarzo, INN-ibalizumab. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-trogarzo_en.pdf."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3389\/fmicb.2017.02323","article-title":"Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy","volume":"8","author":"Iacob","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Singh, K., Sarafianos, S.G., and S\u00f6nnerborg, A. (2019). Long-acting anti-HIV drugs targeting HIV-1 reverse transcriptase and integrase. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020062"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.apsb.2018.01.012","article-title":"Anti-retroviral drugs: Current state and development in the next decade","volume":"8","author":"Zhang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/HIV.S184642","article-title":"Evaluating cabotegravir\/rilpivirine long-acting, injectable in the treatment of HIV infection: Emerging data and therapeutic potential","volume":"ume 11","author":"Fernandez","year":"2019","journal-title":"HIV\/AIDS-Res. Palliat. Care"},{"key":"ref_53","unstructured":"CHMP (2021, June 25). Vocabria, INN-Cabotegravir. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-vocabria_en.pdf."},{"key":"ref_54","first-page":"1","article-title":"HIV pipeline 2019 report","volume":"8591","author":"Colllins","year":"2019","journal-title":"HIV i-B"},{"key":"ref_55","unstructured":"CHMP (2021, June 25). Rekambys, INN-rilpivirine. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-rekambys_en.pdf."},{"key":"ref_56","unstructured":"Orkin, C., Arast\u00e9h, K., G\u00f3rgolas Hern\u00e1ndez-Mora, M., Pokrovsky, V., Overton, E.T., Girard, P.M., Oka, S., D\u2019Amico, R., Dorey, D., and Griffith, S. (2021, June 25). Long-Acting Cabotegravir + Rilpivirine for HIV Maintenance: Flair Week 48 Results. CROI Conference. Conference on Retroviruses and Opportunistic Infections Seattle, Washington. Available online: http:\/\/www.croiconference.org\/sessions\/long-acting-cabotegravir-rilpivirine-hiv-maintenance-flair-week-48-results."},{"key":"ref_57","unstructured":"ViiV Healthcare (2019, October 18). Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02938520."},{"key":"ref_58","unstructured":"AIDSinfo (2019, October 18). Virologic Failure. Definition, Available online: https:\/\/aidsinfo.nih.gov\/understanding-hiv-aids\/glossary\/879\/virologic-failure."},{"key":"ref_59","unstructured":"Collins, S. (2019, September 26). Phase 3 Results with Dual Therapy Cabotegravir\/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies. Available online: http:\/\/i-base.info\/htb\/35812."},{"key":"ref_60","unstructured":"ViiV Healthcare (2019, October 18). Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-acting Rilpivirine fro m Current Antiretroviral Regimen in Virologically Suppressed HIV-1-Infected Adults\u2014Full Text Vie\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02951052."},{"key":"ref_61","unstructured":"(2021, June 25). FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection, Available online: https:\/\/www.fda.gov\/drugs\/human-immunodeficiency-virus-hiv\/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection."},{"key":"ref_62","unstructured":"FDA, and CDER (2021, June 25). CABENUVA- Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212888s000lbl.pdf."},{"key":"ref_63","unstructured":"FDA, and CDER (2021, June 25). VOCABRIA- Highlights of Prescribing Information, Available online: www.fda.gov\/medwatch and https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212887s000lbl.pdf."},{"key":"ref_64","first-page":"127","article-title":"Investigational antiretroviral drugs: What is coming down the pipeline","volume":"25","author":"Gulick","year":"2018","journal-title":"Top. Antivir. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/COH.0000000000000469","article-title":"Fostemsavir: A new CD4 attachment inhibitor","volume":"13","author":"Cahn","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1093\/ofid\/ofy210.555","article-title":"Results of patient-reported outcome data from the phase III BRIGHTE study of fostemsavir","volume":"5","author":"Proudfoot","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_67","unstructured":"CHMP (2021, May 30). Rukobia, INN-fostemsavir. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-rukobia_en.pdf."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/COH.0000000000000479","article-title":"The return of PRO 140, a CCR5-directed mAb","volume":"13","author":"Thompson","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15284336.2018.1452842","article-title":"PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection","volume":"19","author":"Dhody","year":"2018","journal-title":"HIV Clin. Trials"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/157489110790112554","article-title":"PRO 140\u2014A novel CCR5 co-receptor inhibitor","volume":"5","author":"Khatib","year":"2010","journal-title":"Recent Pat. Anti-Infect. Drug Discov."},{"key":"ref_71","unstructured":"CytoDyn, I. (2019, October 18). Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects with CCR5-tropic HIV-1 Infection\u2014Full Text View, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02859961."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1802264","article-title":"Effect of anti-CD4 antibody UB-421 on HIV-1 rebound after treatment interruption","volume":"380","author":"Wang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_73","unstructured":"United BioPharma (2021, June 25). A Multicenter, Single-Arm, 24-Week Study of UB-421 in Combination with Optimized Background Therapy (OBT) Regimen in Patients with Multi-Drug Resistant (MDR) HIV-1 Infection ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03164447."},{"key":"ref_74","unstructured":"United BioPharma (2021, June 25). A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected Adults ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03149211."},{"key":"ref_75","first-page":"1","article-title":"Prospecting for an HIV vaccine","volume":"3","author":"Crowell","year":"2017","journal-title":"Trop. Dis. Travel Med. Vaccines"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/sji.12184","article-title":"HIV vaccines: A brief overview","volume":"80","author":"Lema","year":"2014","journal-title":"Scand. J. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/cpt.1208","article-title":"HIV\/AIDS vaccines","volume":"104","author":"Robinson","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/nnm-2016-0381","article-title":"Vaccine nanoparticles for protection against HIV infection","volume":"12","author":"Aikins","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Brinkkemper, M., and Sliepen, K. (2019). Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies. Vaccines, 7.","DOI":"10.3390\/vaccines7030076"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12981-017-0179-2","article-title":"Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses","volume":"14","author":"Racine","year":"2017","journal-title":"AIDS Res. Ther."},{"key":"ref_82","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID), and Profectus BioSciences INI of HCC (CC) (2019, November 10). Therapeutic Vaccine for HIV\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01859325."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"11440","DOI":"10.1073\/pnas.1101414108","article-title":"Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures","volume":"108","author":"Harris","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","unstructured":"Janssen Vaccines & Prevention, B.V. (2019, November 13). A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus (Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03964415."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/d41586-019-02319-8","article-title":"\u2018Mosaic\u2019 HIV vaccine to be tested in thousands of people across the world","volume":"572","author":"Mega","year":"2019","journal-title":"Nature"},{"key":"ref_86","first-page":"1","article-title":"An Introduction to the Transdermal Delivery of Antiretrovirals","volume":"1","author":"Singh","year":"2014","journal-title":"Adv. Biol. BioMed."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4155\/tde.14.110","article-title":"Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitors","volume":"6","author":"Ham","year":"2015","journal-title":"Ther. Deliv."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Puri, A., Bhattaccharjee, S.A., Zhang, W., Clark, M., Singh, O.N., Doncel, G.F., and Banga, A.K. (2019). Development of a transdermal delivery system for tenofovir alafenamide, a prodrug of tenofovir with potent antiviral activity against HIV and HBV. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11040173"},{"key":"ref_89","first-page":"16","article-title":"Approaches of novel drug delivery systems for Anti-HIV agents","volume":"5","author":"Devendharan","year":"2013","journal-title":"Int. J. Drug. Dev. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ultrasmedbio.2018.10.003","article-title":"Transdermal delivery of enfuvirtide in a porcine model using a low-frequency, low-power ultrasound transducer patch","volume":"45","author":"Snook","year":"2019","journal-title":"Ultrasound Med. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1540-8175.2001.00323.x","article-title":"The use of ultrasound for drug delivery","volume":"18","author":"Tachibana","year":"2001","journal-title":"Echocardiography"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1121\/1.2769980","article-title":"Rectangular cymbal arrays for improved ultrasonic transdermal insulin delivery","volume":"122","author":"Luis","year":"2007","journal-title":"J. Acoust. Soc. Am."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3109\/10717544.2014.935532","article-title":"Permeation enhancer strategies in transdermal drug delivery","volume":"23","author":"Marwah","year":"2014","journal-title":"Drug Deliv."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics11050197","article-title":"Reverse transcriptase inhibitors nanosystems de-signed for drug stability and controlled delivery","volume":"11","author":"Grande","year":"2019","journal-title":"Pharmaceutics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.msec.2016.12.073","article-title":"Stavudine loaded gelatin liposomes for HIV therapy: Preparation, characterization and in vitro cytotoxic evaluation","volume":"73","author":"Nayak","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Mhlwatika, Z., and Aderibigbe, B.A. (2018). Application of dendrimers for the treatment of infectious diseases. Molecules, 23.","DOI":"10.3390\/molecules23092205"},{"key":"ref_97","first-page":"1","article-title":"In-vitro and in-vivo evaluation of poly (propyl ether imine) (petim) dendrimer for sustained delivery of zidov-udine","volume":"S10","author":"Kumar","year":"2013","journal-title":"J. Antivir. Antiretrovir."},{"key":"ref_98","first-page":"3591","article-title":"Enhanced activity of carbosilane den-drimers against HIV when combined with reverse transcriptase inhibitor drugs: Searching for more potent microbicides","volume":"9","author":"Pion","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2147\/IJN.S45886","article-title":"Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system","volume":"9","author":"Sarmento","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"FSO230","DOI":"10.4155\/fsoa-2017-0069","article-title":"Advances in nanomedicine drug delivery applications for HIV therapy","volume":"4","author":"Curley","year":"2018","journal-title":"Futur. Sci. OA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-16703-9","article-title":"Characterization of nanodiamond-based anti-HIV drug delivery to the brain","volume":"8","author":"Roy","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Chaowanachan, T., Krogstad, E., Ball, C., and Woodrow, K.A. (2013). Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061416"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.antiviral.2012.09.015","article-title":"Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis","volume":"96","author":"Date","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Mandal, S., Khandalavala, K., Pham, R., Bruck, P., Varghese, M., Kochvar, A., Monaco, A., Prathipati, P.K., Destache, C., and Shibata, A. (2017). Cellulose acetate phthalate and antiretroviral nanoparticle fabrications for HIV pre-exposure prophylaxis. Polymers, 9.","DOI":"10.3390\/polym9090423"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1166\/jbn.2015.1942","article-title":"Thermosensitive gel containing cellulose acetate phthalate-efavirenz combination nanoparticles for prevention of HIV-1 infection","volume":"11","author":"Date","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2000163","DOI":"10.1002\/adtp.202000163","article-title":"Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates","volume":"4","author":"Sizovs","year":"2021","journal-title":"Adv Ther (Weinh)."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/17\/5305\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:56Z","timestamp":1760165636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/17\/5305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":106,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["molecules26175305"],"URL":"https:\/\/doi.org\/10.3390\/molecules26175305","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]}}}